FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, do not take Stalevo and iron supplements at the same time.
Estonian: Stalevo võib halvendada raua omastamist, seetõttu ärge võtke Stalevo't ja rauapreparaate samaaegselt.
English: - stomach ulcers or convulsions - if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon - any form of severe mental disorder like psychosis - chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.
Estonian: - neerude või hormoonidega seotud haigus - maohaavandid või krambid - kui teil on pikaajaline kõhulahtisus, konsulteerige oma arstiga, kuna see võib olla jämesoole põletiku tunnus - mis tahes raske vaimuhaigus, nt psühhoos - krooniline avatudnurga glaukoom, kuna teie ravimiannust tuleb võib-olla reguleerida ja teie silma siserõhku on vajalik jälgida
English: While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg and 150 mg/37.5 mg/200 mg.
Estonian: Kuigi kogemus karbidopa suuremate päevaste annustega kui 200 mg on vähene, on suurim soovitatav päevane entakapooni annus 2000 mg, seega maksimaalne doos Stalevo tugevustele 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg ja 150 mg/37,5 mg/200 mg on 10 tabletti päevas.
English: stalevo 75/18.75/200 mg [carton only]
Estonian: stalevo 75/18,75/200 mg [ainult karp]
English: Talk to your doctor or pharmacist before taking Stalevo if you have or have ever had: - a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels - asthma or any other disease of the lungs - a liver problem, because your dose may need to be adjusted - kidney or hormone-related diseases
Estonian: Enne Stalevo võtmist pidage nõu oma arsti või apteekriga, kui teil on või on kunagi olnud: - südamelihase infarkt või teisi südamehaigusi, sealhulgas südamearütmiaid või veresoonte haigus - astma või muu kopsuhaigus - probleeme maksaga, kuna teie ravimiannust tuleb võib-olla reguleerida - neerude või hormoonidega seotud haigus - maohaavand või krambid
English: stalevo 125/31.25/200 mg [carton only]
Estonian: stalevo 125/31,25/200 mg [ainult karp]
English: Hepatic impairment: It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment.
Estonian: Maksakahjustus: Stalevo't on soovitav manustada ettevaatusega patsientidele, kellel on leitud maksatalitluse häireid kergest kuni keskmise astmeni.
English: Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo (see section
Estonian: Impulsikontrolli häired: dopamiini agonistide ja/või teiste levodopat sisaldavate dopamiinergiliste ravimite (nt Stalevo) kasutamisel võivad tekkida patoloogiline hasartmängurlus, libiido tõus, hüperseksuaalsus, kompulsiivne kulutamine või ostmine, liigsöömissööstud ja kompulsiivne söömine (vt lõik 4.4).
English: stalevo 175/43.75/200 mg [carton only]
Estonian: stalevo 175/43,75/200 mg [ainult karp]
English: Ten tablets of Stalevo 150 mg/37.5 mg/200 mg equals 375 mg of carbidopa a day.
Estonian: 150 mg/37,5 mg/200 mg Stalevo kümme tabletti vastab 375 mg karbidopa päevadoosile.
English: maprotiline, venlafaxine and paroxetine - rimiterole and isoprenaline, used to treat respiratory diseases - adrenaline, used for severe allergic reactions - noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure - alpha-methyldopa, used to treat high blood pressure - apomorphine, which is used to treat Parkinson's disease.
Estonian: Siia hulka kuuluvad: - depressiooniravimid nagu moklobemiid, amitrüptiliin, desipramiin, maprotiliin, venlafaksiin ja paroksetiin - rimiterool ja isoprenaliin, mida kasutatakse hingamisteede haiguste raviks - adrenaliin, mida kasutatakse raskete allergiliste reaktsioonide puhul - noradrenaliin, dopamiin ja dobutamiin, mida kasutatakse südamehaiguste ja madala vererõhu raviks - alfa-metüüldopa, mida kasutatakse kõrge vererõhu raviks - apomorfiin, mida kasutatakse Parkinsoni tõve raviks.
English: stalevo 150/37.5/200 mg [carton only]
Estonian: stalevo 150/37,5/200 mg [ainult karp]
English: Management of acute overdose with Stalevo therapy is similar to acute overdose with levodopa.
Estonian: Akuutse üleannuse juhul on tegevuskava samasugune kui levodopa üleannustamisel.
English: Stalevo contains sucrose (2.3 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (2,3 mg/tabletis).
English: stalevo 100/25/200 mg [carton only]
Estonian: stalevo 100/25/200 mg [ainult karp]
English: stalevo 50/12.5/200 mg [carton only]
Estonian: stalevo 50/12,5/200 mg [ainult karp]
English: How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Stalevo a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Stalevo tablet strengths can be directly transferred to corresponding Stalevo tablets.
Estonian: a. Patsiendid, keda parajasti ravitakse entakapooni ja standardselt vabaneva levodopa/karbidopa preparaadiga annustes, mis on võrdsed Stalevo tableti toimeainete sisaldusega, võib kohe üle viia ravile Stalevo'ga.
English: stalevo 200/50/200 mg [carton only]
Estonian: stalevo 200/50/200 mg [ainult karp]
English: Stalevo contains sucrose (1.89 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (1,89 mg/tabletis).
English: Stalevo 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Stalevo 75 mg/18,75 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Stalevo 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored filmcoated tablets marked with ‘LCE 150' on one side.
Estonian: Stalevo 150 mg/37,5 mg/200 mg: pruunikas- või hallikaspunane, pikendatud ellipsi kujuline, poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 150”.
English: When considered necessary, the replacement of Stalevo with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.
Estonian: Seega peaks ravimi määrajad olema alati ettevaatlikud, kui asendavad Stalevo levodopa/DDC inhibiitoriga ilma entakapooni või muud dopamiinergilise toimega ravimit lisamata.
English: However, a direct switch from levodopa/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg.
Estonian: Seevastu ei ole kohene üleminek levodopa/DDC inhibiitoritelt Stalevo'le soovitatav patsientide puhul, kellel esineb düskineesia või kelle päevane levodopa annus ületab 800 mg. Neil juhtudel on soovitatav enne üleminekut ravile Stalevo'ga alustada ravi entakapooniga eraldi ravina (entakapooni sisaldavad tabletid) ja kohandada vajadusel levodopa annust.
English: Stalevo 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75' on one side.
Estonian: Stalevo 75 mg/18,75 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 75”.
English: - The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201) - The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).
Estonian: - Teised koostisosad tableti sisus on naatriumkroskarmelloos, magneesiumstearaat, maisitärklis, mannitool (E421) ja povidoon (E1201) - Koostisosad tableti kattes on glütserool (85 protsenti) (E422), hüpromelloos, magneesiumstearaat, polüsorbaat 80, punane raudoksiid (E172), sahharoos, titaandioksiid (E171) ja kollane raudoksiid (E172).
English: - The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize starch, mannitol (E421) and povidone (E1201) - The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, and titanium dioxide (E171).
Estonian: - Teised koostisosad tableti sisus on naatriumkroskarmelloos, magneesiumstearaat, maisitärklis, mannitool (E421) ja povidoon (E1201) - Koostisosad tableti kattes on glütserool (85 protsenti) (E422), hüpromelloos, magneesiumstearaat, polüsorbaat 80, punane raudoksiid (E172), sahharoos ja titaandioksiid (E171).
English: Stalevo 125 mg/31.25 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Stalevo 125 mg/31,25 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Stalevo 125 mg/31.25 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 125' on one side.
Estonian: Stalevo 125 mg/31,25 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 125”.
English: Stalevo 175 mg/43.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Stalevo 175 mg/43,75 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Stalevo or entacapone combined with levodopa/DDC inhibitor.
Estonian: Stalevo või entakapooni ja levodopa/DDC inhibiitori kombinatsioonravi kliinilistel uuringutel on tuvastatud ka raskeid seedetrakti verejookse (aeg-ajalt) ja angioödeemi (harv).
English: Stalevo 200 mg/50 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175).
Estonian: Stalevo 200 mg/50 mg/200 mg on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 ja 175 tabletti).
English: Stalevo contains sucrose (1.9 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (1,9 mg/tabletis).
English: - Each Stalevo 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 125 mg/31,25 mg/200 mg tablett sisaldab 125 mg levodopat, 31,25 mg karbidopat ja 200 mg entakapooni.
English: If this happens, your doctor may need to change the dose of your antiparkinson medicine - experience diarrhoea: monitoring of your weight is recommended in order to avoid potentially excessive weight loss - experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time.
Estonian: - te tunnete, et kontrollimatud liigutused algavad taas või muutuvad hullemaks peale ravi alustamist Stalevo'ga: võtke ühendust oma arstiga, sest vajalikuks võib osutuda parkinsonismivastaste ravimite annuse muutmine - tekib kõhulahtisus: jälgige oma kehakaalu, vältimaks võimalikku ulatuslikku kehakaalu langust - ilmneb suhteliselt lühikese aja jooksul progresseeruv isutus, asteenia, (nõrkus, kurnatus) ja kaalulangus.
English: Stalevo 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100' on one side.
Estonian: Stalevo 100 mg/25 mg/200 mg: pruunikas-või hallikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 100”.
English: Stalevo 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175' on one side.
Estonian: Stalevo 175 mg/43,75 mg/200 mg: hele pruunikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 175”.
English: - Each Stalevo 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 175 mg/43,75 mg/200 mg tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
English: Stalevo contains sucrose (1.6 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (1,6 mg/tabletis).
English: - Each Stalevo 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 75 mg/18,75 mg/200 mg tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
English: - Each Stalevo 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 150 mg/37,5 mg/200 mg tablett sisaldab 150 mg levodopat, 37,5 mg karbidopat ja 200 mg entakapooni.
English: - Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.
Estonian: - Pikaajalise ravi korral Stalevo'ga on soovitatav perioodiliselt kontrollida maksa-, vereloome-, kardiovaskulaar- ja neerufunktsiooni.
English: Stalevo 75 mg/18.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 75 mg/18,75 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: Stalevo 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50' on one side.
Estonian: Stalevo 50 mg/12,5 mg/200 mg: pruunikas-või hallikaspunane, ümar, kumer poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 50”.
English: Stalevo contains sucrose (1.2 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (1,2 mg/tabletis).
English: - Each Stalevo 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 50 mg/12,5 mg/200 mg tablett sisaldab 50 mg levodopat, 12,5 mg karbidopat ja 200 mg entakapooni.
English: Stalevo contains sucrose (1.4 mg/tablet).
Estonian: Stalevo sisaldab sahharoosi (1,4 mg/tabletis).
English: - Each Stalevo 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 100 mg/25 mg/200 mg tablett sisaldab 100 mg levodopat, 25 mg karbidopat ja 200 mg entakapooni.
English: The safety of levodopa, carbidopa or entacapone in the infant is not known.
Estonian: Levodopa, karbidopa ja entakapooni ohutus imikule on teadmata ja seetõttu ei tohiks ema ravi ajal Stalevo'ga last imetada.
English: Stalevo 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200' on one side.
Estonian: Stalevo, 200 mg/50 mg/200 mg: tume pruunikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 200”.
English: - Each Stalevo 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Stalevo 200 mg/50 mg/200 mg tablett sisaldab 200 mg levodopat, 50 mg karbidopat ja 200 mg entakapooni.
English: Stalevo 150 mg/37.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 150 mg/37,5 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: EU/1/03/260/024 10 film-coated tablets EU/1/03/260/025 30 film-coated tablets EU/1/03/260/026 100 film-coated tablets EU/1/03/260/027 130 film-coated tablets EU/1/03/260/028 175 film-coated tablets
Estonian: EU/1/03/260/024 10 õhukese polümeerikattega tabletti EU/1/03/260/025 30 õhukese polümeerikattega tabletti EU/1/03/260/026 100 õhukese polümeerikattega tabletti EU/1/03/260/027 130 õhukese polümeerikattega tabletti EU/1/03/260/028 175 õhukese polümeerikattega tabletti
English: Stalevo 50 mg/12.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 50 mg/12,5 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: EU/1/03/260/029 10 film-coated tablets EU/1/03/260/030 30 film-coated tablets EU/1/03/260/031 100 film-coated tablets EU/1/03/260/032 130 film-coated tablets EU/1/03/260/033 175 film-coated tablets
Estonian: EU/1/03/260/029 10 õhukese polümeerikattega tabletti EU/1/03/260/030 30 õhukese polümeerikattega tabletti EU/1/03/260/031 100 õhukese polümeerikattega tabletti EU/1/03/260/032 130 õhukese polümeerikattega tabletti EU/1/03/260/033 175 õhukese polümeerikattega tabletti
English: Stalevo 125 mg/31.25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 125 mg/31,25 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Stalevo 125 mg/31,25 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: EU/1/03/260/034 10 film-coated tablets EU/1/03/260/035 30 film-coated tablets EU/1/03/260/036 100 film-coated tablets EU/1/03/260/037 130 film-coated tablets EU/1/03/260/038 175 film-coated tablets
Estonian: EU/1/03/260/034 10 õhukese polümeerikattega tabletti EU/1/03/260/035 30 õhukese polümeerikattega tabletti EU/1/03/260/036 100 õhukese polümeerikattega tabletti EU/1/03/260/037 130 õhukese polümeerikattega tabletti EU/1/03/260/038 175 õhukese polümeerikattega tabletti
English: Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Stalevo 175 mg/43,75 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: Stalevo 175 mg/43.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 175 mg/43,75 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: EU/1/03/260/005 10 film-coated tablets EU/1/03/260/006 30 film-coated tablets EU/1/03/260/007 100 film-coated tablets EU/1/03/260/008 250 film-coated tablets EU/1/03/260/014 175 film-coated tablets EU/1/03/260/017 130 film-coated tablets
Estonian: EU/1/03/260/005 10 õhukese polümeerikattega tabletti EU/1/03/260/006 30 õhukese polümeerikattega tabletti EU/1/03/260/007 100 õhukese polümeerikattega tabletti EU/1/03/260/008 250 õhukese polümeerikattega tabletti EU/1/03/260/014 175 õhukese polümeerikattega tabletti EU/1/03/260/017 130 õhukese polümeerikattega tabletti
English: EU/1/03/260/009 10 film-coated tablets EU/1/03/260/010 30 film-coated tablets EU/1/03/260/011 100 film-coated tablets EU/1/03/260/012 250 film-coated tablets EU/1/03/260/015 175 film-coated tablets EU/1/03/260/018 130 film-coated tablets
Estonian: EU/1/03/260/009 10 õhukese polümeerikattega tabletti EU/1/03/260/010 30 õhukese polümeerikattega tabletti EU/1/03/260/011 100 õhukese polümeerikattega tabletti EU/1/03/260/012 250 õhukese polümeerikattega tabletti EU/1/03/260/015 175 õhukese polümeerikattega tabletti EU/1/03/260/018 130 õhukese polümeerikattega tabletti
English: Stalevo 100 mg/25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 100 mg/25 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: EU/1/03/260/001 10 film-coated tablets EU/1/03/260/002 30 film-coated tablets EU/1/03/260/003 100 film-coated tablets EU/1/03/260/004 250 film-coated tablets EU/1/03/260/013 175 film-coated tablets EU/1/03/260/016 130 film-coated tablets
Estonian: EU/1/03/260/001 10 õhukese polümeerikattega tabletti EU/1/03/260/002 30 õhukese polümeerikattega tabletti EU/1/03/260/003 100 õhukese polümeerikattega tabletti EU/1/03/260/004 250 õhukese polümeerikattega tabletti EU/1/03/260/013 175 õhukese polümeerikattega tabletti EU/1/03/260/016 130 õhukese polümeerikattega tabletti
English: EU/1/03/260/019 10 film-coated tablets EU/1/03/260/020 30 film-coated tablets EU/1/03/260/021 100 film-coated tablets EU/1/03/260/022 130 film-coated tablets EU/1/03/260/023 175 film-coated tablets
Estonian: EU/1/03/260/019 10 õhukese polümeerikattega tabletti EU/1/03/260/020 30 õhukese polümeerikattega tabletti EU/1/03/260/021 100 õhukese polümeerikattega tabletti EU/1/03/260/022 130 õhukese polümeerikattega tabletti EU/1/03/260/023 175õhukese polümeerikattega tabletti
English: 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets each day.
Estonian: - Kui võtate Stalevo 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg või 150 mg/37,5 mg/200 mg tablette, ärge võtke üle 10 tableti päevas.
English: Stalevo 200 mg/50 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Stalevo 200 mg/50 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects.
Estonian: Kui teil on tunne, et Stalevo toime on liiga tugev või liiga nõrk või olete märganud kõrvaltoimeid, rääkige sellest oma arstile või apteekrile.
English: London, 11 July 2007 EMEA/CHMP/75066/2007
Estonian: London, 11. juuli 2007 EMEA/CHMP/75066/2007
English: The Reference Member State was the Netherlands and the Concerned Member States were Austria, Germany, Ireland, Italy, and United Kingdom.
Estonian: Viiteliikmesriik oli Madalmaad ja asjaomased liikmesriigid olid Austria, Saksamaa, Iirimaa, Itaalia ja Ühendkuningriik.
English: A positive opinion was adopted by on 24 January 2007.
Estonian: Positiivne otsus võeti vastu 24. jaanuaril 2007.
English: The Mutual Recognition Procedure started on 28 January 2006.
Estonian: Vastastikuse tunnustamise menetlus algas 28. jaanuaril 2006.
English: The Rapporteur was Dr Ian Hudson and Co-Rapporteur was Dr Bengt Ljungberg.
Estonian: Ettekandja oli dr Ian Hudson ja kaasettekandja dr Bengt Ljungberg.
English: The final opinion was converted into a Decision by the European Commission on 11 July 2007.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 11. juulil 2007.
English: The Marketing Authorisation Holder provided written explanations on 20 October 2006.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 20. oktoobril 2006.
English: The Netherlands referred the reasons for disagreement to the EMEA on 7 July 2006.
Estonian: Madalmaad esitasid lahkarvamuse põhjused EMEAle 7. juulil 2006.
English: The arbitration procedure started on 27 July 2006 with the adoption of a list of questions.
Estonian: Vahekohtumenetlus algas 27. juulil 2006 küsimuste loetelu kinnitamisega.
English: Significant differences have been identified with regard to dose in urinary tract infections and of the maximum adult daily dose.
Estonian: Olulisi erinevusi tuvastati seoses kuseteede nakkuste korral kasutatavate annuste ja täiskasvanu ööpäevase suurima annusega.
English: In addition, it was considered that the applicant should include in the Summary of Product Characteristics (point 5.1) the organisms listed in the breakpoints and susceptibility table relevant to the indications, as per the Note for Guidance on Evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev.1).
Estonian: Lisaks leiti, et taotleja peab lisama ravimi omaduste kokkuvõttesse (punkti 5.1) piirväärtuste ja tundlikkuse tabelis nimetatud, näidustustega asjakohaste organismide loetelu, vastavalt bakterinakkuste raviks näidustatud ravimite hindamise suunistes (CPMP/EWP/558/95 versioon 1) sätestatule.